Zenith Epigenetics’ has developed a cutting-edge epigenetic platform, generating differentiated, potent, and selective BET protein inhibitors. In conjunction with our clinical collaborators at leading oncology institutions, we are developing combination therapies, pairing novel BET inhibitors with targeted agents, for multiple oncology indications with significant unmet need. This approach aims to overcome drug resistance, increase the rate and duration of responses, and ultimately, improve patient outcomes. Leveraging translational medicine to decipher drivers of disease and insight into the mechanism of action, Zenith is developing patient enrichment and selection strategies to maximize the benefit of epigenetic combination therapies for patients.
Our lead candidate, ZEN-3694, is in a Phase 2 randomized trial for the treatment of prostate cancer and in multiple proof of concept sold tumor trials including NUT carcinoma, breast, lung, ovarian, pancreatic, colorectal cancer and malignant peripheral nerve sheath tumor (MPNST). For NUT carcinoma, ZEN-3694 in combination with a CDK4/6i has shown remarkable activity and has been granted Fast Track status by the FDA.
Zenith Captial Corp. held its annual general meeting on January 15, 2025. The comapny organized a live webcast of the event, which included a presentation by President and CEO Donald McCaffrey.
A replay of the webcast will be available for one month following the conclusion of the event, and may be accessed using the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=xHIoxeIO.
Zenith Capital Corp. President & Chief Executive Officer, Donald McCaffrey, presented on the Emerging Growth Conference on September 25, 2024.
This live, interactive online event gave existing shareholders and the investment community the opportunity to interact with Mr. McCaffrey in real time.
You can watch a video of the presentation HERE
